A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2010 ◽
Vol 4
◽
pp. CMU.S4960
◽
2008 ◽
Vol 62
(11)
◽
pp. 1675-1683
◽
Keyword(s):